T1	intervention 62 72	Duloxetine
T2	control 80 87	Placebo
T3	condition 92 134	Aromatase Inhibitor-Associated Arthralgias
T4	eligibility 604 775	AI-treated postmenopausal women with early-stage breast cancer and who had average joint pain score of â‰¥ 4 out of 10 that developed or worsened since AI therapy initiation
T5	outcome-Measure 878 913	average joint pain through 12 weeks
T6	total-participants 1173 1176	299
T7	intervention-participants 1196 1199	127
T8	control-participants 1237 1240	128
T9	outcome 1320 1344	average joint pain score
T11	outcome 1588 1624	Rates of adverse events of any grade
T12	iv-bin-percent 1670 1673	78%
T13	cv-bin-percent 1676 1679	50%
T10	outcome 1517 1533	worst joint pain
T14	outcome 1535 1550	joint stiffness
T15	outcome 1552 1569	pain interference
T16	outcome 1575 1586	functioning
T17	outcome 1682 1713	rates of grade 3 adverse events
